Oxurion: Pierre Fabre Adopts Exagis Platform from its Subsidiary Axiodis
Oxurion announced on Monday that Pierre Fabre Laboratories is utilizing Exagis, its proprietary clinical data management platform developed by its subsidiary Axiodis. This adoption by a major pharmaceutical group represents a commercial validation of the solution among established sector players.
A Pharmaceutical Giant Adopts Oxurion's Platform
Pierre Fabre Laboratories is deploying Exagis, the Clinical Data Management System (CDMS) designed by Axiodis, the biometric subsidiary of the Oxurion group. The ongoing use by the French laboratory represents a commercial validation of the value proposed by Exagis to a leading pharmaceutical player. Initially designed to meet the strict requirements for collecting and structuring clinical data, the platform has gradually evolved into a broader clinical data management system, now capable of meeting the needs for efficiency, compliance, and standardization of trial sponsors.
A Modular Architecture for All Client Profiles
Exagis was designed as a modular and scalable solution, capable of adapting to a wide range of study configurations and organizational models. This positioning allows the platform to serve sponsors of all sizes, from emerging biotechnology companies to established large pharmaceutical groups. Aline Stennevin, Global Medical Advisor at Pierre Fabre Dermo-Cosmetics, states: 'We seek solutions that combine ease of use, operational rigor, and regulatory compliance. Exagis meets these expectations with a pragmatic approach, specifically designed for clinical teams and the operational realities of the field.'
A Catalyst for the Group's Software Strategy
This adoption by Pierre Fabre reinforces Oxurion's ambition to establish Exagis as a strategic software asset at the core of its development trajectory. The group aims to establish this platform as a strategic software asset, combining expertise in clinical operations, software innovation, and proprietary operational data to serve sponsors of pharmaceutical, biotechnological, and medical device solutions.
